BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
SHR-A1811: trial readouts and FDA decisions
4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer | recruiting | 150 |
| 2026-12-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuz | active not recruiting | 381 |
| 2026-12-31 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06413745 Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Can | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | active not recruiting | 59 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05482568 A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | recruiting | 324 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P1/P2 | Shanghai Shengdi Pharmaceutical Co., Ltd | NCT07231211 A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | Solid Tumors | recruiting | 258 |
| 2026-10 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2026-08 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | Gastric Cancer; Gastroesophageal-junction Cancer | recruiting | 200 |
| 2026-07-15 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06057610 A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | HER2-PositiveRecurrent or Metastatic Breast Cancer | active not recruiting | 868 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.